Ardsley Advisory Partners LP Aldeyra Therapeutics, Inc. Transaction History
Ardsley Advisory Partners LP
- $568 Million
- Q4 2024
A detailed history of Ardsley Advisory Partners LP transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Ardsley Advisory Partners LP holds 1,150,000 shares of ALDX stock, worth $7.73 Million. This represents 1.01% of its overall portfolio holdings.
Number of Shares
1,150,000
Previous 500,000
130.0%
Holding current value
$7.73 Million
Previous $2.7 Million
112.91%
% of portfolio
1.01%
Previous 0.48%
Shares
11 transactions
Others Institutions Holding ALDX
# of Institutions
127Shares Held
37.6MCall Options Held
757KPut Options Held
539K-
Perceptive Advisors LLC New York, NY9.28MShares$62.3 Million1.54% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$36.8 Million17.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$25.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$24.3 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.47MShares$9.87 Million0.17% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $392M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...